濮阳东方医院咨询医生热线濮阳东方妇科医院咨询专家在线,濮阳东方医院割包皮手术专业,濮阳东方医院看男科收费正规,濮阳东方男科医院电话咨询,濮阳东方口碑如何,濮阳东方医院男科治疗早泄评价很不错,濮阳东方医院看妇科病收费低

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

LOS ANGELES, March 7 (Xinhua) -- U.S. food producer Unilever said on Monday it is recalling two varieties of its Skippy peanut butter because some jars may be contaminated with salmonella.The recall affects jars distributed to retailers in 16 states -- Arkansas, Connecticut, Delaware, Illinois, Iowa, Maine, Minnesota, Missouri, Nebraska, New Hampshire, New Jersey, New York, North Dakota, Pennsylvania, Virginia and Wisconsin, the company said.But the company said no illnesses have been linked to the contaminated Skippy peanut butter.The 16.3-ounce jars are marked with UPC codes 048001006812 and 048001006782 and have Best-If-Used-By Dates of MAY1612LR1, MAY1712LR1, MAY1812LR1, MAY1912LR1, MAY2012LR1 and MAY2112LR1.Unilever advised consumers in a press release to throw away any jars of the recalled peanut butter and to contact the company for a replacement coupon.Salmonella is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. The most common symptoms are diarrhea, abdominal cramps and fever within eight hours to 72 hours of eating a contaminated product.About 40,000 cases of salmonella are reported each year in the United States, according to the Centers for Disease Control and Prevention.

WUHAN, Feb. 8 (Xinhua) -- Ten people were comfirmed dead and nine others injured when a farmer's tricycle rolled over into an 8-meter deep gully at about 2:30 p.m. Monday at a village in Lichuan City, Hubei province.Eight passengers were found dead on the spot. The eleven wounded were hastened to the hospital. But two of them died on the way.Sources with the Lichuan government said the farmer's vehicle carried the passengers illegally. The rescue operation continued until midnight. The actual cause for accident was still under investigation.

WASHINGTON, May 11 (Xinhua) -- NASA's Dawn spacecraft has obtained its first image of the giant asteroid Vesta, which will help fine-tune navigation during its approach, the U.S. space agency announced Wednesday.Dawn expects to achieve orbit around Vesta on July 16, when the asteroid is about 117 million miles from Earth.The image from Dawn's framing cameras was taken on May 3 when the spacecraft began its approach and was approximately 752,000 miles (1.21 million km) from Vesta. The asteroid appears as a small, bright pearl against a background of stars. Vesta also is known as a protoplanet, because it is a large body that almost formed into a planet."After plying the seas of space for more than a billion miles, the Dawn team finally spotted its target," said Carol Raymond, Dawn's deputy principal investigator at NASA's Jet Propulsion Laboratory in Pasadena, California. "This first image hints of detailed portraits to come from Dawn's upcoming visit."Vesta is 330 miles (530 km) in diameter and the second most massive object in the asteroid belt. Ground- and space-based telescopes obtained images of the bright orb for about two centuries, but with little surface detail.Mission managers expect Vesta's gravity to capture Dawn in orbit on July 16. To enter orbit, Dawn must match the asteroid's path around the sun, which requires very precise knowledge of the body's location and speed. By analyzing where Vesta appears relative to stars in framing camera images, navigators will pin down its location and enable engineers to refine the spacecraft's trajectory.Dawn will start collecting science data in early August at an altitude of approximately 1,700 miles (2,700 km) above the asteroid's surface. As the spacecraft gets closer, it will snap multi-angle images allowing scientists to produce topographic maps. Dawn will later orbit at approximately 120 miles (200 km) to perform other measurements and obtain closer shots of parts of the surface. Dawn will remain in orbit around Vesta for one year. After another long cruise phase, Dawn will arrive in 2015 at its second destination, Ceres, an even more massive body in the asteroid belt.Gathering information about these two icons of the asteroid belt will help scientists unlock the secrets of our solar system's early history. The mission will compare and contrast the two giant asteroids shaped by different forces. Dawn's science instruments will measure surface composition, topography and texture. Dawn also will measure the tug of gravity from Vesta and Ceres to learn more about their internal structures. The spacecraft's full odyssey will take it on a 3-billion-mile (5-billion-km) journey, which began with its launch in September 2007.

BEIJING, May 23 (Xinhuanet) -- A new study suggests that crossing your arms could reduce the intensity of pain, according to media reports.The study was conducted by researchers from University College London (UCL), who reported their finding in the journel Pain.They said that crossing the arms could confuse the brain and conflicting information between the brain's two maps - one for the person's body and the other for external space - leading to a lower sensation of pain.A laser was used to generate a four millisecond pin prick on the hands of eight volunteers, who experienced this twice with their arms at their sides and arms crossed.Then the participants were asked to rate the intensity of pain in two situations and an EEG (electroencephalography) was used to measure their electrical brain responses.The results showed that both the perception of pain and EEG activity was reduced when the arms were crossed."Perhaps when we get hurt, we should not only 'rub it better' but also cross our arms," said Giandomenico Iannetti of UCL's department of physiology, pharmacology and neuroscience.